DOI 10.3389/fimmu.2025.1651568
A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab.
Аннотация
BACKGROUND
Psoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases with common pathogenesis, such as the involvement of IL-17A, which also plays an essential role in the development and metastasis of colorectal cancer. Xeligekimab, a novel IL-17A inhibitor, offers a targeted therapeutic approach for these conditions.
CASE PRESENTATION: A 43-year-old male presented with a 12-year history of plaque psoriasis and hidradenitis suppurativa. Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. His comorbidities include chronic hepatitis B managed with 10-year antiviral therapy and metastatic colorectal cancer treated with synchronous resection of liver metastases during primary tumor surgery 6 years ago (no recurrence).
RESULTS
After 28 weeks of xeligekimab treatment, the patient experienced significant improvement in symptoms and skin lesions. The evaluation indicators demonstrated a sustained decline: PASI decreased from 51 to 0.8, BSA from 87% to 6%, DLQI from 20 to 1, and Hurley staging improved to Grade I. During follow-up, imaging and tumor marker testing revealed no signs of tumor and hepatitis B progression.
CONCLUSION
Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.